Cited 0 times in
Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구남수 | - |
dc.contributor.author | 김무현 | - |
dc.contributor.author | 김신영 | - |
dc.contributor.author | 김정호 | - |
dc.contributor.author | 백예지 | - |
dc.contributor.author | 손유진 | - |
dc.contributor.author | 송영구 | - |
dc.contributor.author | 안진영 | - |
dc.contributor.author | 염준섭 | - |
dc.contributor.author | 이경화 | - |
dc.contributor.author | 정수진 | - |
dc.contributor.author | 조윤숙 | - |
dc.contributor.author | 최준용 | - |
dc.contributor.author | 현종훈 | - |
dc.contributor.author | 안미영 | - |
dc.date.accessioned | 2021-12-28T16:49:41Z | - |
dc.date.available | 2021-12-28T16:49:41Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186815 | - |
dc.description.abstract | Purpose: Coronavirus disease-2019 (COVID-19) is a novel respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); there are few specific treatments. Convalescent plasma (CP), donated by people who have recovered from COVID-19, is an investigational therapy for severe or critically ill patients with COVID-19. Materials and methods: This retrospective cohort study evaluated the effectiveness of CP therapy in patients with severe or life-threatening cases of COVID-19 at two hospitals in Seoul, Korea, between May and September 2020. Clinical outcomes were evaluated in 20 patients with CP therapy in a descriptive manner. Additionally, the changes in cycle threshold (Ct) values of 10 patients with CP therapy were compared to those of 10 controls who had the same (±0.8) initial Ct values but did not receive CP. Results: Of the 20 patients (mean age 66.6 years), 18 received high-dose oxygen therapy using mechanical ventilators or high-flow nasal cannulas. Systemic steroids were administered to 19 patients who received CP. The neutralizing antibody titers of the administered CP were between 1:80 and 1:10240. There were two ABO-mismatched transfusions. The World Health Organization ordinal scale score and National Institutes of Health severity score improved in half of the patients within 14 days. Those who received CP showed a higher increase in Ct values at 24 h and 72 h after CP therapy compared to controls with similar initial Ct values (p=0.002). No transfusion-related side effects were observed. Conclusion: CP therapy may be a potential therapeutic option in severe or critically ill patients with COVID-19. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | COVID-19* / therapy | - |
dc.subject.MESH | Critical Illness | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunization, Passive* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | United States | - |
dc.title | Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | YunSuk Cho | - |
dc.contributor.googleauthor | YuJin Sohn | - |
dc.contributor.googleauthor | JongHoon Hyun | - |
dc.contributor.googleauthor | YaeJee Baek | - |
dc.contributor.googleauthor | MooHyun Kim | - |
dc.contributor.googleauthor | JungHo Kim | - |
dc.contributor.googleauthor | JinYoung Ahn | - |
dc.contributor.googleauthor | SuJin Jeong | - |
dc.contributor.googleauthor | NamSu Ku | - |
dc.contributor.googleauthor | Joon Sup Yeom | - |
dc.contributor.googleauthor | MiYoung Ahn | - |
dc.contributor.googleauthor | DongHyun Oh | - |
dc.contributor.googleauthor | JaePhil Choi | - |
dc.contributor.googleauthor | SinYoung Kim | - |
dc.contributor.googleauthor | KyoungHwa Lee | - |
dc.contributor.googleauthor | YoungGoo Song | - |
dc.contributor.googleauthor | JunYong Choi | - |
dc.identifier.doi | 10.3349/ymj.2021.62.9.799 | - |
dc.contributor.localId | A00189 | - |
dc.contributor.localId | A04521 | - |
dc.contributor.localId | A00675 | - |
dc.contributor.localId | A00902 | - |
dc.contributor.localId | A05921 | - |
dc.contributor.localId | A05924 | - |
dc.contributor.localId | A02037 | - |
dc.contributor.localId | A02267 | - |
dc.contributor.localId | A02353 | - |
dc.contributor.localId | A04620 | - |
dc.contributor.localId | A03638 | - |
dc.contributor.localId | A05940 | - |
dc.contributor.localId | A04191 | - |
dc.contributor.localId | A05944 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 34427065 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | Convalescent plasma treatment | - |
dc.subject.keyword | cycle threshold (Ct) value | - |
dc.subject.keyword | neutralizing antibody | - |
dc.contributor.alternativeName | Ku, Nam Su | - |
dc.contributor.affiliatedAuthor | 구남수 | - |
dc.contributor.affiliatedAuthor | 김무현 | - |
dc.contributor.affiliatedAuthor | 김신영 | - |
dc.contributor.affiliatedAuthor | 김정호 | - |
dc.contributor.affiliatedAuthor | 백예지 | - |
dc.contributor.affiliatedAuthor | 손유진 | - |
dc.contributor.affiliatedAuthor | 송영구 | - |
dc.contributor.affiliatedAuthor | 안진영 | - |
dc.contributor.affiliatedAuthor | 염준섭 | - |
dc.contributor.affiliatedAuthor | 이경화 | - |
dc.contributor.affiliatedAuthor | 정수진 | - |
dc.contributor.affiliatedAuthor | 조윤숙 | - |
dc.contributor.affiliatedAuthor | 최준용 | - |
dc.contributor.affiliatedAuthor | 현종훈 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 799 | - |
dc.citation.endPage | 805 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.62(9) : 799-805, 2021-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.